|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||21.90|
|Dividend & Yield||1.03 (3.23%)|
|1y Target Est||N/A|
In the first half of 2017, Roche’s (RHHBY) Alecensa generated revenues of CHF 148.0 million.
Announcement: Moody's: Yestar's acquisition of IVD distributor in line with expectations; ratings unaffected. Global Credit Research- 22 Sep 2017. Hong Kong, September 22, 2017-- Moody's Investors Service ...
In the first half of 2017, Roche’s (RHHBY) Esbriet reported revenues of CHF 418.0 million, which reflected a ~16.0% growth on a YoY basis.